Migraine
8 competing products in clinical development for Migraine.
Pipeline by Phase
Phase 12
Phase 24
Phase 31
Approved1
All Products (8)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Galcanezumab + Erenumab | Eli Lilly | Approved | Completed | 43 |
| Lasmiditan + Placebo | Eli Lilly | Phase 3 | Completed | 40 |
| Lasmiditan + Placebo | Eli Lilly | Phase 2 | Completed | 35 |
| DFN-15 Dose A (treatment A) + DFN-15 Dose B (treatment B) | Dr. Reddy's Laboratories | Phase 2 | Completed | 32 |
| lasmiditan 200 mg + Sumatriptan + matching placebo | Eli Lilly | Phase 1 | Completed | 29 |
| DFN-15 (fasted) + DFN-15 (fed) + Comparator Celebrex® (fed) | Dr. Reddy's Laboratories | Phase 1 | Completed | 26 |
| ABP-450 + Placebo | AEON Biopharma | Phase 2 | Completed | 25 |
| ABP-450 | AEON Biopharma | Phase 2 | Terminated | 17 |